Is TB-500 Legal in Australia? Prescription, Import and Supply Rules

How TB-500 is treated under Australian law

TB-500 is commonly marketed as a thymosin beta-4–related peptide. In Australia, products intended for human therapeutic use are regulated as therapeutic goods. TB-500 is not included on the Australian Register of Therapeutic Goods (ARTG), so it is considered an unapproved medicine.

In practice, TB-500 for human use is generally captured by prescription-only (Schedule-type) controls and subject to state/territory poisons legislation. Supply must involve an Australian-registered prescriber and a compliant pharmacy, and many pharmacies will not supply TB-500 at all. Clinics must use TGA pathways for unapproved medicines and meet strict record-keeping and patient consent requirements.

Check if a prescription pathway applies to you

Unapproved medicine pathways that may be used

Because TB-500 is not ARTG-listed, a doctor would generally need to apply one of the TGA’s unapproved access pathways:

• SAS Category B: Case-by-case TGA application with clinical justification and patient consent.
• Authorised Prescriber: Prescriber seeks authorisation for a defined patient group; requires ethics or HREC approval in many cases.

Approval is not guaranteed. Even with a pathway in place, a pharmacy may decline supply, and ongoing review is common as regulatory scrutiny of peptide compounding remains high.

Speak with a clinician about SAS/Authorised Prescriber

Import rules: can you bring TB-500 into Australia?

The TGA Personal Importation Scheme allows certain medicines to be imported for personal use under strict conditions. For TB-500, these conditions are especially important:

• You must hold a valid Australian prescription before import.
• No more than 3 months’ supply per import and no more than 15 months’ supply in 12 months.
• The product must not be otherwise prohibited or restricted and must be properly labelled.
• Goods marketed as “research chemicals” for human use can still be treated as therapeutic goods and seized.

Border Force may seize shipments of unapproved or mislabelled injectables even when importers claim personal use. Supplying others or advertising imported TB-500 is unlawful.

Ask about import compliance and seizure risks

Advertising and supply restrictions you should know

• No consumer advertising: Australian law prohibits advertising prescription-only medicines and unapproved therapeutic goods to the public.
• Supply only via lawful channels: Selling TB-500 online to Australians without scripts or outside TGA pathways breaches the Therapeutic Goods Act and state poisons laws.
• Clinic claims: Claims about benefits, dosing and safety for unapproved medicines must not mislead and must comply with TGA guidance; many online sellers do not comply.

Report a non-compliant ad or get advice

Sports and anti‑doping considerations

Thymosin beta-4–related compounds are prohibited by the World Anti-Doping Agency (WADA). Athletes using TB-500 risk anti‑doping rule violations, sanctions, and potential health risks from unverified products.

Get athlete-safe guidance

Safety and quality risks with grey‑market TB-500

• Unknown purity and strength; frequent mislabelling and contamination.
• Non-sterile injectables and unsafe handling practices.
• Lack of clinical oversight, interaction checks and adverse event monitoring.
• Border seizure, fines and legal exposure for unlawful import or supply.

Discuss safer, compliant routes

Frequently asked questions

Still unsure? Ask our team

Ask a clinician about TB-500 legality and access

Have a specific situation? Share a few details and a clinician-focused team member will respond with general guidance on lawful options in Australia.